Cervical Cancer Screening for the Primary Care Physician

Clinical Practice Guideline
MedStar Health

"*These guidelines are provided to assist physicians and other clinicians in making decisions regarding the care of their patients. They are not a substitute for individual judgment brought to each clinical situation by the patient's primary care provider in collaboration with the patient. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication but should be used with the clear understanding that continued research may result in new knowledge and recommendations".*

1. Recommendations

MedStar Health endorses the USPSTF and ACOG guidelines on cervical cancer screening.

Cervical Cancer Screening initiation and periodicity in Average Risk Patients

	Age to Start	**Method and Frequency**	**Age to Stop**	**s/p Vaginal Hysterectomy**
USPSTF 2018 and ACOG 2021	Age 21	Age 21-29: cytology q 3 yrs. Age 30-65: co-testing q 5 yrs. (or cytology q 3 yrs. or HPV testing alone q 5 yrs.)	Age 65 if adequately screened (3 neg cytologies or 2 neg HPV screens in prior 10 yrs., 1 of which in the past 5 yrs.)	No need if cervix is gone and no h/o cervical cancer or CIN 2 or greater

Cervical Cancer Screening initiation and periodicity in High-Risk Patients

Condition	**Age to start**	**Method**	**Frequency**	**Age to Stop**
HIV and immunosuppressed	Within 1 yr. of sexual activity	Cytology Or Cytology with HPV co-testing beginning age 30	Cytology—annually, then q 3 yrs. after three negative annual screens Co-testing—q 3 yrs. after first negative co-test	Continue screening throughout lifetime, stopping based on a shared discussion regarding quality of life and remaining life expectancy rather than age

Initial Approval Date and Reviews: June 2013, June 2015, June 2017, June 2019, June 2021, June 2023.

(Replaced Management of Abnormal Pap smear, created 1997)

Most Recent Revision and Approval Date: June 2023

Next Scheduled Review Date:

June 2025 Ambulatory Best Practice

DES exposed		Cervical and vaginal cytology	Annually	until a woman is no longer a candidate for intervention

Follow up of abnormal Pap Smears—General Principles—2019 ASCCP Risk-Based Management Consensus Guidelines:

- Current management guidelines have shifted from test results-based algorithms to a risk-based approach based on the risk of precancer (CIN3+), or 5-year risk of progressing to precancer or cancer. Risk tables using patient age, current screening results and prior screening results have been developed and are accessible at http://asccp.org
- iOS and Android mobile apps, and a Web application are available to help guide management of abnormal pap smears: asccp.org/mobile app
- In general, this risk-based algorithm applies to women aged 25-65 years.
- For management of Patients Ages < 25 years with cytologic abnormalities (see Figure 12).

A note on HPV vaccination—The latest CDC guidelines for the HPV vaccine:

- HPV vaccine is recommended for routine vaccination at age 11 or 12 years. (Vaccination can be started at age 9.)
  - Two doses of HPV vaccine are recommended for most persons starting the series before their 15th birthday.
  - The second dose of HPV vaccine should be given 6 to 12 months after the first dose.
  - Adolescents who receive two doses less than 5 months apart will require a third dose of HPV vaccine.
- Vaccination is recommended for everyone through age 26 years if not adequately vaccinated when younger.
  - Three doses of HPV vaccine are recommended for teens and young adults who start the series at ages 15 through 26 years, and for immunocompromised persons.
  - The recommended three-dose schedule is 0, 1–2 and 6 months.
- Some adults ages 27 through 45 years may decide to get the HPV vaccine if they did not get adequately vaccinated when younger, based on discussion with their clinician. HPV vaccination of people in this age range provides less benefit, for several reasons.
- HPV vaccine works best when given before any exposure to HPV.

General Principles: Since its introduction in 1943, the Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer and remains the mainstay of early detection of cervical intraepithelial neoplasia. Recently, increasing understanding of the role of high-risk strains of the Human Papilloma Virus in the development of invasive cervical cancer, and the ability to test for these strains, has begun to affect the screening guidelines for cervical cancer. Despite these improvements, most invasive cervical cancers in the US are in women who have never been screened or have not been screened in the last five years, and these women are often in underserved patient populations. Technological advances in screening techniques will only offer a significant improvement in overall cancer incidence if they reach all women in the US.

Cervical Cancer Screening in Average-Risk Women

- **Method**:
  - **Liquid based cytology**: The sample is collected as in the conventional Pap but then the brush suspends the sample cells in a fixative solution, disperses them, and then selectively collects cells on a filter. Liquid based cytology permits HPV testing to be done on the same sample.
  - When two devices are used to collect the specimen, the ectocervical device should be used first.

- **Screening Initiation and Periodicity**:
  - The United States Preventive Services Task Force (USPSTF), American Cancer Society (ACS) and American College of Obstetricians and Gynecologists (ACOG) have all issued guidelines on cervical cancer screening. **MedStar Health endorses the USPSTF and ACOG recommendations, as below:**
    - All average-risk women should begin cervical cancer screening at age 21, regardless of history of sexual activity or other risk factors. Cervical cytology screening prior to age 21 should be avoided.
    - 21—29 years of age: Cervical cytology screening is recommended every 3 years. with reflex to HPV for all pathology.
    - 30-65 years of age: The *preferred* method is Cytology with high-risk HPV co-testing every 5 years or HPV testing alone; Cytology alone every 3 years is acceptable.
    - >65 years of age: Cervical cytology screening may stop for those women with adequate screening history (Either 3 consecutive negative pap smear results, or 2 consecutive negative co-tests within the last ten years, with the last occurring within 5 years and no history of CIN2 in the last 20 years). Screening should not recommence for any reason, including having a new sexual partner. Following spontaneous regression or adequate

treatment of CIN2, CIN3, or adenocarcinoma in situ, screening should continue for 25 years.

- Post-total hysterectomy (removal of uterus and cervix): Cervical cytology screening may stop for those women **without** history of CIN2 or higher-grade lesion, even if there is no history of adequate screening. Again, screening should not resume for any reason. For those women **with a history of CIN, AIS or cancer**, Pap smear screening via cervical cytology only should continue for 25 years regardless of whether the cervix is present or absent.

- Women immunized against HPV: Continue to screen according to the age-specific recommendations for the general population.
- Cytology more often than every 3 years and the use of cytology/high risk HPV co-testing more often than every 5 years for routine screening should be avoided.
- Testing for non-high-risk strains of HPV has no utility in cervical cancer screening and should not be employed

The ACS guideline recommends postponing the age for screening initiation to 25 and relying on HPV screening alone as the preferred methodology. MedStar does not endorse these guidelines.

Cervical Cancer Screening in High-Risk Patients

Patients with HIV, immunosuppressed women and women exposed to Diethylstilbestrol (DES) in utero are considered high risk. The ACOG and experts in cervical cancer research and care provide recommendations for screening in these populations.

Patients with HIV and those who are immunosuppressed are less likely to clear HPV that is acquired (meaning it is more likely to persist) and pre-malignant cervical changes may progress more quickly to cervical cancer. Women considered immunosuppressed include:

- Recipients of solid organ transplants
- Recipients of allogeneic hematopoietic stem cell transplants
- Patients with inflammatory bowel disease on immunosuppressant treatment
- Patients with SLE
- Patients with RA on immunosuppressant treatment

Cervical cancer in DES "daughters" is a non-HPV mediated condition. Consequently, screening relies on cytology rather than HPV testing. In addition to cervical cancer, DES daughters are at increased risk for cervical and vaginal clear cell adenocarcinoma.

Cervical Cancer Screening initiation and periodicity in High-Risk Patients

Condition	Age to start	Method	Frequency	Age to Stop
HIV and immunosuppressed	Within 1 yr. of sexual activity	Cytology Or Cytology with HPV co-testing beginning age 30	Cytology—annually, then q 3 yrs. after three negative annual screens Co-testing—q 3 yrs. after first negative co-test	Continue screening throughout lifetime, stopping based on a shared discussion regarding quality of life and remaining life expectancy rather than age
DES exposed		Cervical and vaginal cytology	Annually	until a woman is no longer a candidate for intervention

Initial Approval Date and Reviews: June 2013, June 2015, June 2017, June 2019, June 2021, June 2023.

(Replaced Management of Abnormal Pap smear, created 1997)

Most Recent Revision and Approval Date: June 2023

Next Scheduled Review Date:

June 2025 Ambulatory Best Practice

Results Classification System: Bethesda System

The Bethesda System was the creation of a standardized framework for laboratory reports that included a descriptive diagnosis and an evaluation of specimen adequacy.

Specimen Adequacy	• Satisfactory • Unsatisfactory
General Categorization	**Interpretation/Result**
A. Negative for intraepithelial lesion or malignancy Includes: • "Within normal limits" • "Benign cellular changes"	Organisms may be present including: • *Trichomonas vaginalis* • Fungal organisms morphologically consistent with *candida* species • Shift in flora suggestive of bacterial vaginosis • Bacteria morphologically consistent with • *Actinomyces* species • Cellular changes consistent with herpes simplex virus Other non-neoplastic findings (*optional to report; list not comprehensive*) Reactive cellular changes associated with inflammation (includes typical repair)
B. Epithelial cell abnormality	• Atypical Squamous Cells of Undetermined Significance (ASCUS) • Low-grade squamous intraepithelial lesion • (LSIL) • Cannot exclude HSIL (ASC-H) • High-grade squamous intraepithelial lesion • (HSIL) • Squamous cell carcinoma
C. Glandular cells present	• Endometrial cells (may be benign or require further evaluation if post-menopausal) • Atypical glandular cells (AGC) may be atypical endometrial or endocervical cells • Atypical glandular cells, favor neoplastic • Adenocarcinoma in situ (AIS) • Endocervical adenocarcinoma in situ • Adenocarcinoma

D. Others	• Cases in which there are no morphological abnormalities in the cells per se; however, the findings may indicate some increased risk: for example, benign-appearing "Endometrial cells in a woman 40 years of age" • Other neoplasms identified, like small cell carcinoma

Follow up of abnormal Pap Smears—General Principles—2019 ASCCP Risk-Based Management Consensus Guidelines:

- Current management guidelines have shifted from test results-based algorithms to a risk-based approach based on the risk of precancer (CIN3+), or 5-year risk of progressing to precancer or cancer. Risk tables using patient age, current screening results and prior screening results have been developed and are accessible at http://asccp.org
- iOS and Android mobile apps, and a Web application are available to help guide management of abnormal pap smears: asccp.org/mobile-app
- In general, this risk-based algorithm applies to women age 25-65.
- For management of Patients Ages < 25 years with cytologic abnormalities see Figure 12.
- After abnormal cervical cancer screening test results for patients 25 years or older, colposcopic biopsy results, or treatment of histologic HSIL, surveillance with either HPV testing alone or co-testing is preferred
- HPV testing and co-testing are more sensitive than cytology alone in detecting CIN 2+ in both the post-colposcopy and posttreatment settings.

Patient Education/Counseling:

- https://www.acog.org/Patients/FAQs/Cervical-Cancer-Screening
- Pamphlets (American College of Obstetricians and Gynecologists Online Bookstore): https://sales.acog.org/Cervical-Cancer-Screening-P464.aspx
- JAMA Patient Page: August 21, 2018. Cervical Cancer Screening **https://jamanetwork.com/journals/jama/fullarticle/2697698**



- HPV test results are the basis for risk estimation
- Equal management is recommended for equal risk regardless of the combination of factors determining risk.
- Management recommendations include return to routine screening, 1 yr. or 3 yr. surveillance, colposcopy, or treatment
- An immediate risk of CIN3+ ≥ 4% requires referral for colposcopy or treatment
- A new abnormal screening test results following a negative HPV test or co-test within the past 5 yrs. reduced the estimated CIN3 risk by 50%
- The risk-based management algorithm tool is accessible at https://app.asccp.org/

Initial Approval Date and Reviews: June 2013, June 2015, June 2017, June 2019, June 2021, June 2023. (Replaced Management of Abnormal Pap smear, created 1997)	**Most Recent Revision and Approval Date: June 2023** 	**Next Scheduled Review Date:** June 2025 Ambulatory Best Practice

Follow up of abnormal results outside the risk-based strategy

The following clinical situations should be managed outside the risk-based algorithm

Women younger than age 25 (Figure 12):

- Cytologic abnormalities in this age group are likely to represent non 16/18 HPV strains and have a high risk of regression and low risk of rapid progression to cancer. Management is therefore more conservative.
- ASC-US, HPV negative, does not need observation. These patients can continue with routine screening.
- Low grade abnormalities ASCUS HPV +, ASCUS HPV unknown, and LSIL can be managed with repeat cytology at 1 and 2 yrs. After two negative cytology results, the patient can return to routine screening.
    - Cytology if age < 25 years
    - HPV-based testing if ≥ 25
- Colposcopy is recommended for high grade cytology at any time (HSIL, ASC-H) or for persistent low-grade cytology at 2 yrs. Expedited treatment is not recommended in this age group.

Follow up of Unsatisfactory Cytology (Figure 5):

- In cases where HPV is unknown (any age) or negative (age ≥ 25), age-based screening should be repeated in 2-4 months.
- In those women 25 years or older where HPV is positive (unknown genotype), age-based screening can be repeated in 2-4 months, or the patient may be referred directly to colposcopy
- Women with a positive test for HPV 16 or 18 should be referred for colposcopy.

Follow up of Cytology Negative but Endocervical or Transformation Zone Lacking:

- Ages 21-29, routine screening
- Ages 30-65, it is preferred that HPV testing be performed.
    - If the HPV is negative, the woman should undergo routine screening (the preferred co-testing in 5 years or the acceptable option of cytology alone in 3 years).
    - If the HPV testing is positive, manage using the appropriate risk-based guideline.
    - If HPV testing cannot be performed on the initial sample, cytology should be repeated in 3 years.

Initial Approval Date and Reviews: June 2013, June 2015, June 2017, June 2019, June 2021, June 2023. (Replaced Management of Abnormal Pap smear, created 1997)	**Most Recent Revision and Approval Date: June 2023**	**Next Scheduled Review Date:** June 2025 Ambulatory Best Practice

ASC-H on cytology:

- Refer for colposcopy regardless of HPV results since the rate of cancer is similar irrespective of HPV results

HPV 18 and HPV 16 positive, NILM (negative for intraepithelial lesion or malignancy):

- Refer for colposcopy

Two consecutive unsatisfactory screening tests:

- Refer for colposcopy

Pregnant woman:

- Pregnant women should be managed the same as non-pregnant women except endocervical curettage and endometrial biopsy are contraindicated, and excisional biopsy should be performed only if cancer is suspected.

Immunosuppressed patients of any age:

- Colposcopy is recommended for all results of HPV positive ASCUS or higher. If HPV testing is not performed on ASCUS results, repeat cytology in 6-12 mos. is recommended with colposcopy for ASCUS or higher.

Women who have undergone hysterectomy for treatment of cervical abnormalities:

- Manage with 3 annual HPV based tests followed by long term surveillance with HPV based testing every three years for 25 yrs.

Women over age 65 with prior abnormalities:

- Manage according to the guidelines for women 25-65.

Patients with hysterectomy (uterus and cervix) for benign disease:

- Screening is not recommended, but ASCUS HPV positive and LSIL should be managed with follow up in 12 months.
- HSIL, ASC-H, AGC should be managed with immediate vaginal colposcopy

Initial Approval Date and Reviews: June 2013, June 2015, June 2017, June 2019, June 2021, June 2023. (Replaced Management of Abnormal Pap smear, created 1997)	**Most Recent Revision and Approval Date: June 2023**	**Next Scheduled Review Date:** June 2025 Ambulatory Best Practice

Follow Up of Abnormal Pap Smear Results- 2019 Guidelines ASCCP

Result	Age	Follow up Step 1	Follow up Step 2
Unsatisfactory Cytology, HPV negative or unknown	All	Repeat age-based screening 2-4 months	Abnormalà f/u per guidelines Negative àroutine screening per age guidelines Still unsatisfactory àcolposcopy
Unsatisfactory Cytology, HPV Positive*	≥25	Either A) age-based screening 2-4 months Or B) referral to colposcopy *Women with HPV 16 or 18 should be referred for colposcopy	Abnormalà follow up per guidelines Negative àroutine screening per age guidelines (since HPV+ this is co-testing one year, or if HPV 16/18 + à colposcopy) Still unsatisfactory àcolposcopy
Cytology Negative but Endocervical Component or Transformation Zone Absent	21-29 & 30-65 ≥30 HPV unknown ≥30 HPV negative ≥30 HPV positive	Routine screening Add on HPV testing (preferred), Cytology in 3 yrs. Routine screening Manage per risk-based guideline	
ASC-H (atypical cells cannot exclude high grade lesion)	All	Colposcopy	
Atypical Glandular Cells (including endometrial)	All	Colposcopy with endocervical sampling if not pregnant and endometrial sampling if ≥ 35 or < 35 and at risk for endometrial neoplasia	

Initial Approval Date and Reviews: June 2013, June 2015, June 2017, June 2019, June 2021, June 2023.

(Replaced Management of Abnormal Pap smear, created 1997)

Most Recent Revision and Approval Date: June 2023

Next Scheduled Review Date:

June 2025 Ambulatory Best Practice

Result	Age	Follow up Step 1	Follow up Step 2
ASCUS, LSIL, HSIL with or without HPV	25-65	Manage per risk-based guideline	
ASCUS HPV +, ASCUS HPV unknown, LSIL	21-24	Repeat cytology at 1 and 2 yrs. colposcopy for high grade cytology at any point; colposcopy if persistent low-grade cytology at 2 yrs.	After two negative cytology results, the patient can return to routine screening. • Cytology if age < 25 years • HPV-based testing if ≥ 25
ASCUS HPV negative	21-24	Routine screening (cytology in 3 yrs.)	
ASC-H/HSIL	21-24	Colposcopy	
Cytology negative, HPV Positive	≥30	Either a) Repeat co-testing 1 yr. Or b) Genotyping for HPV 16/18	Cytology neg/HPV negà co-testing 3 yrs. ASCUS or higher or HPV pos à colposcopy Positiveà colposcopy Negativeà cotesting one year and follow guideline above

Pelvic Exams when cervical cancer screening is not needed:

Both the United States Preventive Services Task Force (USPSTF) and American College of Obstetricians and Gynecologists (ACOG) state that there is insufficient evidence to recommend screening pelvic exams in asymptomatic women. ACOG recommends that pelvic exams be performed when indicated by medical history or symptoms and if, after a discussion of risks and benefits, the patient prefers the examination. Whether a pelvic exam is performed or not, discussion of reproductive and sexual health issues remains an important part of the health maintenance examination for women.

Initial Approval Date and Reviews: June 2013, June 2015, June 2017, June 2019, June 2021, June 2023. (Replaced Management of Abnormal Pap smear, created 1997)	Most Recent Revision and Approval Date: June 2023	Next Scheduled Review Date: June 2025 Ambulatory Best Practice

Figure 3: Initial Workup of Atypical Glandular Cells (AGC)



Initial Approval Date and Reviews: June 2013, June 2015, June 2017, June 2019, June 2021, June 2023. (Replaced Management of Abnormal Pap smear, created 1997)	Most Recent Revision and Approval Date: June 2023 	Next Scheduled Review Date: June 2025 Ambulatory Best Practice

Figure 5: Unsatisfactory Cytology



Initial Approval Date and Reviews: June 2013, June 2015, June 2017, June 2019, June 2021, June 2023. (Replaced Management of Abnormal Pap smear, created 1997)	**Most Recent Revision and Approval Date: June 2023** 	**Next Scheduled Review Date:** June 2025 Ambulatory Best Practice

Figure 12: Management of Patients Ages < 25 years with Cytologic Abnormalities



Initial Approval Date and Reviews: **June 2013, June 2015, June 2017, June 2019, June 2021, June 2023.** (Replaced Management of Abnormal Pap smear, created 1997)	**Most Recent Revision and Approval Date: June 2023**	**Next Scheduled Review Date:** June 2025 Ambulatory Best Practice

References

1. U.S. Preventive Services Task Force (USPSTF): August 2018 Screening for Cervical Cancer: www.uspreventiveservicestaskforce.org
2. Updated Cervical Cancer Screening Guidelines. https://www.acog.org/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines.
3. Fontham, Elizabeth et al. Cervical Cancer Screening for Individuals at Average Risk: Guideline Update from the American Cancer Society. CA Cancer J Clin 2020; 70: 321-346.
4. American Congress of Obstetricians and Gynecologists (ACOG): Committee Opinion Number 463: Cervical Cancer in Adolescents: Screening, Evaluation and Management, August 2010
5. American Congress of Obstetricians and Gynecologists (ACOG): Practice Bulletin: Number 99: Management of Abnormal Cervical Cytology and Histology, December 2008, Reaffirmed 2010
6. American Congress of Obstetricians and Gynecologists (ACOG): Primary and Preventive Care: Annual Women's Healthcare, 2012
7. Perkins RB, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24(2): 102.Huh WK, et al. Use of primary high-risk human papilloma virus testing for cervical cancer screening: Interim clinical guidance, Gynecol Oncol (2015)
8. Sawaya, G et al. "Cervical Cancer Screening in Average Risk Women: Best Practice Advice from the Clinical Guidelines Committee of the American College of Physicians Cervical Cancer Screening in Average-Risk Women," Ann Intern Med. Published online 30 April 2015 Doi: 10.7326/M14-2426
9. U.S. Preventive Services Task Force (USPSTF): March 2017 Gynecological Conditions: Periodic Screening with the Pelvic Exam: www.uspreventiveservicestaskfoce.org.
10. Huh et al. Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Guidance. J Lower Gen Tract Dis 2015;19: 91–9.
11. The Utility of and Indications for Routine Pelvic Examination. ACOG Committee Opinion number 754. Obstetrics and Gynecology 2018; 132: e174-e180.
12. Moscicki et al. Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. Journal of Lower Genital Tract Disease. 2019; 23: 87-101.

Initial Approval Date and Reviews: June 2013, June 2015, June 2017, June 2019, June 2021, June 2023. (Replaced Management of Abnormal Pap smear, created 1997)	**Most Recent Revision and Approval Date: June 2023** 	**Next Scheduled Review Date:** June 2025 Ambulatory Best Practice